All In Biotech

Drug Trial Radar · NCT03168438

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Open-Label Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

6

Actual

Start

Aug 18, 2017

Primary completion

Jul 13, 2020

Study completion Nov 5, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
May 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.

Conditions

  • Neoplasms

Interventions

  • Letetresgene autoleucelDrug

    Letetresgene autoleucel (GSK3377794) as an IV infusion

  • Letetresgene autoleucel with pembrolizumabDrug

    Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks

  • FludarabineDrug

    Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

  • CyclophosphamideDrug

    Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

  • PembrolizumabDrug

    Pembrolizumab is available as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 108 weeks
  2. Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm OnlyTime frame: Up to 3 weeks
  3. Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to BaselineTime frame: Up to 108 weeks
  4. Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to BaselineTime frame: Up to 108 weeks
  5. Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to 108 weeks
  6. Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) FindingsTime frame: Up to 108 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Duarte, California

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.